Skip to main content

Edwards Lifesciences Corp cash flow statement

  • EW · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$107.15+1.28%Close 13 Nov 2026 · Market value $61.51B

In fiscal 2025 (the year to 31 Dec 2025), Edwards Lifesciences Corp generated $1.60B of operating cash flow and $1.33B of free cash flow, after $260.2M of capital expenditure.

From Edwards Lifesciences Corp's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Edwards Lifesciences Corp cash flow statement, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Net income$128.9M$229.1M$218.0M$236.7M$291.5M$389.1M$811.1M$494.9M$569.5M$583.6M$722.2M$1.05B$823.4M$1.50B$1.52B$1.40B$4.17B$1.07B$1.02B
Depreciation & amortization$55.60M$58.70M$56.50M$58.00M$53.70M$62.90M$68.60M$65.80M$71.20M$81.90M$77.40M$89.30M$107.2M$134.8M$139.6M$144.9M$155.2M$156.6M$171.2M
Stock-based compensation$28.70M$28.30M$29.30M$35.00M$42.10M$47.40M$48.30M$49.90M$56.90M$61.60M$71.00M$81.30M$92.60M$109.3M$126.8M$139.4M$162.3M$158.1M$172.8M
Operating cash flow$153.2M$165.3M$251.4M$308.2M$362.1M$472.7M$1.02B$549.7M$704.4M$1.00B$926.7M$1.18B$1.05B$1.73B$1.22B$895.8M$542.3M$1.60B$1.72B
Operating cash flow margin12.4%12.5%17.4%18.4%19.1%23.1%44.0%22.0%23.8%29.1%24.9%27.2%24.0%33.1%27.3%17.9%10.0%26.3%25.7%
Capital expenditures$50.60M$64.00M$61.80M$76.60M$109.0M$109.0M$82.90M$102.7M$176.1M$168.1M$238.7M$254.4M$407.0M$325.8M$244.6M$253.0M$252.4M$260.2M$292.8M
Acquisitions———$42.60M$36.60M$0.00$15.00M$331.6M$0.00$192.9M$0.00$100.2M$0.00$0.00—————
Free cash flow$102.6M$101.3M$189.6M$231.6M$253.1M$363.7M$939.4M$447.0M$528.3M$832.6M$688.0M$928.5M$647.3M$1.41B$973.6M$642.8M$289.9M$1.33B$1.42B
Free cash flow margin8.3%7.7%13.1%13.8%13.3%17.8%40.4%17.9%17.8%24.2%18.5%21.4%14.8%26.9%21.8%12.8%5.3%22.0%21.3%
Free cash flow per share$0.14$0.14$0.27$0.32$0.36$0.53$1.44$0.68$0.81$1.29$1.07$1.46$1.02$2.23$1.56$1.05$0.48$2.28$2.46
Gross share repurchases$306.5M$95.50M$200.0M$303.4M$344.1M$496.9M$300.9M$280.1M$662.3M$763.3M$795.5M$263.3M$625.4M$512.8M$1.73B$879.6M$1.16B$893.4M$754.6M
Stock issuance proceeds———————$63.60M$73.10M$77.60M$103.7M$110.4M$79.20M$82.20M$64.80M$83.40M$90.60M$89.20M—
Net share repurchases$306.5M$95.50M$200.0M$303.4M$344.1M$496.9M$300.9M$216.5M$589.2M$685.7M$691.8M$152.9M$546.2M$430.6M$1.66B$796.2M$1.07B$804.2M$754.6M
Cash interest paid$7.30M$2.70M$2.40M$3.20M$4.40M$4.30M$15.50M$14.10M$16.10M$19.90M$30.10M$19.90M$19.90M$20.20M$19.30M$19.90M$19.60M$20.20M—
Free cash flow after SBC$73.90M$73.00M$160.3M$196.6M$211.0M$316.3M$891.1M$397.1M$471.4M$771.0M$617.0M$847.2M$554.7M$1.30B$846.8M$503.4M$127.6M$1.18B$1.25B

Quarterly

Edwards Lifesciences Corp cash flow statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Net income$369.9M$351.9M$366.3M$3.07B$385.6M$358.0M$333.2M$291.1M$91.20M$380.7M$241.9M$307.5M
Depreciation & amortization$36.70M$38.50M$39.60M$34.50M$42.60M$36.60M$38.10M$39.20M$42.70M$40.90M$42.70M$44.90M
Stock-based compensation$30.50M$44.60M$43.90M$42.10M$31.70M$40.20M$37.50M$41.20M$39.20M$45.40M$42.20M$46.00M
Operating cash flow$136.6M−$53.50M$371.5M$351.8M−$127.5M$280.4M$290.2M$573.7M$450.9M$43.80M$651.9M$570.3M
Operating cash flow margin10.8%−4.0%27.1%26.0%−9.2%19.8%18.9%36.9%28.7%2.7%37.4%33.2%
Capital expenditures$88.30M$65.30M$85.40M$51.90M$49.80M$56.00M$49.30M$57.50M$97.40M$64.90M$66.90M$63.60M
Free cash flow$48.30M−$118.8M$286.1M$299.9M−$177.3M$224.4M$240.9M$516.2M$353.5M−$21.10M$585.0M$506.7M
Free cash flow margin3.8%−8.9%20.9%22.1%−12.8%15.9%15.7%33.2%22.5%−1.3%33.6%29.5%
Free cash flow per share$0.08−$0.20$0.47$0.50−$0.30$0.38$0.41$0.88$0.61−$0.04$1.01$0.88
Gross share repurchases$448.4M$200.0K$158.1M$901.0M$100.1M$258.6M$5.50M$588.7M$40.60M$421.8M$153.3M$138.9M
Net share repurchases$448.4M$200.0K$158.1M$901.0M$100.1M$258.6M$5.50M$588.7M$40.60M$421.8M$153.3M$138.9M
Free cash flow after SBC$17.80M−$163.4M$242.2M$257.8M−$209.0M$184.2M$203.4M$475.0M$314.3M−$66.50M$542.8M$460.7M

The main figures as JSON and plain text. See data and methodology.

EW in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.